Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Patients with Eales' disease, chorioretinitis, central serous retinopathy, or malignant choroidal melanoma were tested for HLA antigen deviation. When corrected p values (pc) are used, the first three disorders did not show any significant deviation, whereas a significant increase of HLA-Aw32 (pc = 0.026) was found in the malignant melanoma group. For conclusive evidence the latter finding needs confirmation by analysis of a greater number of patients with this disorder.
Invest Ophthalmol Vis Sci 1978 Sep
PMID:Missing evidence for HLA antigen association with Eales' disease, chorioretinitis, central serous retinopathy, and malignant choroidal melanoma. 70 Sep 71

Computed tomography proved insensitive to leptomeningeal spread of hematologic malignancies including leukemia, lymphoma, and malignant histiocytosis. In only 3% of patients did it directly demonstrate leptomeningeal tumor. In comparison, the detection rate of leptomeningeal tumor secondary to carcinoma was 44% and for melanoma, 100%. Intracranial subarachnoid seeding from primary brain gliomas was detected in each instance. The simultaneous presence of parenchymal metastases with leptomeningeal carcinomatosis occurred in 18% of patients with nonhematologic malignancies. Computed tomography evidence of communicating hydrocephalus, previously thought to be a major factor in clinical symptomatology, occurred in only 11% of patients.
J Comput Assist Tomogr 1978 Sep
PMID:Computed tomography in leptomeningeal spread of tumor. 70 24

A selected series of 669 primary malignant melanomas of the skin, stage I, has been classified according to Clark's system into lentigo maligna melanoma (86), superficial spreading malignant melanoma (259), nodular malignant melanoma (194) and unclassifiable malignant melanoma (130). It was often difficult to distinguish between lentigo maligna melanoma and superficial spreading malignant melanoma, and sometimes also between this last type and nodular melanoma. There seem to be borderline cases between the respective types. The 10-year specific cumulative survival rate (approximately the cure rate) was 98.3% for the lentigo maligna melanomas, 78.6% for nodular malignant melanomas and 76.7% for the unclassifiable group of melanomas. The 5-year observed prognosis ofthe 3 main types is satisfactory compared with other investigations. As the prognosis of the 3 types of cutaneous malignant melanoma differs considerably the use of this classification is recommended. The number of unclassifiable cases is likely to be reduced in the routine work when several sections of each tumour are studied.
Acta Pathol Microbiol Scand A 1978 Sep
PMID:A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. I. Histological classification, sex and age of the patients, localization of tumour and prognosis. 71 5

A series of 60 primary cutaneous malignant melanomas has been studied by serial block technique. The resulting 492 sections have been classified as junctional naevus with or without atypia and preinvasive or invasive malignant melanoma according to Clark (1967). No sections showed lentigo maligna (melanoma). The overall classification resultedin 49 superficial spreading malignant melanomas, 6 nodular malignant melanomas and 5 unclassifiable malignant melanomas. In 3 cases (5%) there was inconsistency between the classification of the central section and the overall classification of the tumour. Five theoretical growth patterns have been postulated ranging from thatof the pure superficial spreading malignant melanoma completely surrounded by a preinvasive area to the pure nodular malignant melanoma which completely lacks any such area. Borderline cases between these two types certainly seem to exist. Features such as intraepidermal Pagetoid growth of tumour cells, co-existence of a benign melanocytic component and histological changes indicating tumour regression have been discussed. It is recommended that at least 3 tissue blocks should be taken from all malignant melanomas up to 25 mm in diameter and more if the tumour is larger.
Acta Pathol Microbiol Scand A 1978 Sep
PMID:The classification of primary cutaneous malignant melanoma. A prospective study of 60 cases using Clark's classification. 71 6

A presentation is given of a malignant melanoma of the choroid of a 15-year-old girl. The tumor was erroneously considered as to be a subretinal hemorrhage produced by a choroidal rupture after an accident. A beginning melanosis bulbi resulted in the enucleation and the histological examination of the eye, which confirmed malignant melanoma of the choroid.
Klin Monbl Augenheilkd 1978 Sep
PMID:[An error in the fluorescence angiographic diagnosis of a subretinal process (author's transl)]. 75 Jul 1

Recent advances in our understanding of the pathology and prognosis of malignant melanoma make possible rationally designed immunotherapeutic studies. A number of immunologic studies suggest that there may be a specific immune response to melanoma-associated antigens in patients with melanoma; however, other studies have shown lack of specificity, so this issue remains to be definitively resolved. New immunotherapeutic agents, including BCG, TF, and levamisole, among others, offer the potential for improving therapy for patients.
J Invest Dermatol 1976 Sep
PMID:Malignant melanoma. 78 36

The therapeutic activity of ftorafur was compared to that of 5-fluorouracil (5-FU) in a number of tumor systems. The drugs were active against ip L1210 leukemia when administered ip, sc, or orally. Administration every fourth day x 3 proved to be the most effective treatment schedule for both drugs, although significant activity was seen on all treatment schedules tested. Both congeners had activity against sc implanted L1210 leukemia as well as a limited effect on the ic implanted tumor. 5-FU produced greater increases in lifespan of mice bearing L1210 leukemia than did ftorafur. 5-FU was also more effective against ip B16 melanoma and ip Gardner 6C3HED lymphosarcoma. Ftorafur was ineffective in the treatment of mice bearing ip P388 leukemia, a tumor which is quite sensitive to 5-FU. At approximately equimolar doses both drugs produced a persistent inhibition of 2'-deoxyuridine incorporation into DNA of L1210 cells in vivo. Ftorafur produced a greater inhibition of uridine incorporation into RNA than did 5-FU, which may account for the lower therapeutic activity of ftorafur. In combination chemotherapy of L1210 leukemia 5-FU plus ftorafur was no more effective than 5-FU alone, neither of the congeners was synergistic with either adriamycin or actinomycin D, and in combination with methotrexate therapeutic synergism was observed with 5-FU but not with ftorafur. After eight transplant generations of exposure to ftorafur, a subline of L1210 leukemia became totally resistant to ftorafur and simultaneously cross-resistant to 5-FU. Doses of ftorafur and 5-FU which were optimally effective in mice bearing the parental L1210 line were lethal to mice implanted with the ftorafur-resistant subline. When treatment of the resistant subline was discontinued after nine transplant generations of exposure to ftorafur, sensitivity to 5-FU returned after three transplant generations without ftorafur. The subline retained its resistance to ftorafur until eight transplant generations after cessation of ftorafur treatment. Another subline of L1210 leukemia exposed to 5-fU for 20 transplant generations proved to be completely resistant to 5-fu and cross-resistant to ftorafur. The mutual cross-resistance between ftorafur and 5-FU supports the contention that ftorafur acts primarily as a depot form of 5-FU.
Cancer Treat Rep 1976 Sep
PMID:Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. 79 50

Three groups of 24 C57BL/6J black mice were studied. One group was implanted with B16 malignant melanoma, another was implanted with mammary adenocarcinoma, and the third was not given tumor implants. After 14 to 17 days, the mice were given injections i.v. of technetium-99m sulfur colloid and killed 30 min later. Organs were weighed, and radioactivity was counted. The ratios of specific radioactivities of the spleens to those of the liver were higher only in the group of mice bearing malignant melanomas. This finding suggests that the "hot spleen" phenomenon observed in humans with malignant melanomas may be due to increased specific activity rather than increased splenic volume.
Cancer Res 1977 Sep
PMID:Distribution of technetium-99m sulfur colloid in mice bearing melanomas or mammary carcinomas. 88 76

The value of prophylactic node dissection was studied in 147 patients with nonsuperficial malignant melanoma of cutaneous origin; all had clinical stage I disease. Seventy-three patients had prophylactic node dissection and 74 did not. Survival rates were calculated by the actuarial method and were age and sex adjusted. Five-year crude survival rates for these two groups were 62 and 29%, respectively, and the adjusted rates were 70 and 33%, respectively. These significant differences (P less than 0.001) were maintained at 10 years. The difference in survival in the two groups cannot be explained on the basis of age, sex, year of operation, size or location of the primary tumour, or previous incisional biopsy. It is concluded that prophylactic node dissection contributed appreciably to increased survival in this study.
Can J Surg 1977 Sep
PMID:Prophylactic node dissection for malignant melanoma. 89 Jun 16

A 43-year-old man with metastatic malignant melanoma was treated with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in combination with imidazole carboxamide and hydroxyurea. He achieved complete remission. After 22 months of chemotherapy, the patient developed bilateral pulmonary infiltrates. Open lung biopsy showed sclerosing alveolitis. Long-term therapy with BCNU may cause pulmonary fibrosis, as has been seen with other cytotoxic drugs.
Chest 1977 Sep
PMID:Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea. 89 Dec 93


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>